Abstract Library

#3244 Efficacy and safety of immune checkpoint inhibitors in patients with neuroendocrine neoplasia: Report of a case series from a large tertiary centre

Introduction: Immune checkpoint inhibitors (ICI) have changed our view on how to treat cancer. Despite their approved treatment of many different cancers, efficacy of ICI in neuroendocrine neoplasia is limited and poorly understood. Established treatment options of neuroendocrine tumors (NET) and carcinomas (NEC) are based on surgery, tumor-targeted medical treatments, peptide guided radioreceptor therapy (PRRT) and locoregional therapies. However, in many patients these treatments lose efficacy over time, and novel therapies are urgently needed.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Özdirik B, Jann H, Tacke F, Wiedenmann B, Roderburg C,

Keywords: checkpoint inhibitor, neuroendocrine neoplasia, PD-L1,

#3240 miR-29b serum levels are down-regulated in patients with neuroendocrine tumors

Introduction: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Özdirik B, Mohr R, Jann H, Geisler L, Tacke F,

Keywords: neuroendocrine tumor, miRNA, miR-29, prognosis, biomarker,

#3237 Soluble urokinase Plasminogen Activator Receptor (suPAR) serum levels are elevated in patients with neuroendocrine neoplasia

Introduction: Neuroendocrine neoplasia (NEN) represent a heterogeneous group of malignancies that might be challenging to diagnose. In case of advanced disease stages and especially in cases of poorly differentiated (G3) NEN, patients face a dismal prognosis. Therefore, innovative biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options might help to improve clinical management of these patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Burcin �, Mohr R, Jann H, Geisler L, Tacke F,

Keywords: suPAR, neuroendocrine tumor, biomarker, prognosis,

#3224 MicroRNAs - 193 and -223 alter NET differentiation markers and shape inflammatory response in vitro

Introduction: Future improvements in NETs therapy depend on treatments tailored to tumor cell characteristics, microenvironment and inflammatory status. We recently reported selective downregulation of microRNAs (miRs) -29 and -223 in serum of NET patients, suggesting a possible role in NET disease.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Geisler L, Özdirik B, Mohr R, Knorr J, Tacke F,

Keywords: miR, NET, BON, in vitro, biomarker, inflammation,

#3194 miR-223 - A potential diagnostic biomarker in gastroenteropancreatic neuroendocrine tumors

Introduction: MicroRNAs (miRNAs) are key regulators of tumor biology, with functions that range from an oncogene to a tumor suppressor. They are proposed as diagnostic, prognostic and predictive circulating or tissue-based biomarkers in several human diseases, especially carcinoma. However, their role in pathogenesis of neuroendocrine neoplasia remains incompletely elucidated, and emerging insights still await translation into clinical treatment modalities.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Özdirik B, Mohr R, Geisler L, Tacke F, Jann H,

Keywords: miR-21, miR-223, gastroenteropancreatic, neuroendocrine tumor, diagnostic, biomarker,